Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod in generalized myasthenia gravis
NCT03669588Phase 3Completed
- Sponsor
- argenx
- Start
- Aug 2018
- Primary completion
- Apr 2020
- Modality
- Antibody Fragments
- Countries
- 16
01
Overview
A Phase 3 trial of efgartigimod alfa in myasthenia gravis (MG), sponsored by argenx. Started Aug 2018; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT03669588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03669588.